JP6965362B2 - ポリペプチド、ポリペプチド断片及びその誘導体、並びに応用 - Google Patents

ポリペプチド、ポリペプチド断片及びその誘導体、並びに応用 Download PDF

Info

Publication number
JP6965362B2
JP6965362B2 JP2019548059A JP2019548059A JP6965362B2 JP 6965362 B2 JP6965362 B2 JP 6965362B2 JP 2019548059 A JP2019548059 A JP 2019548059A JP 2019548059 A JP2019548059 A JP 2019548059A JP 6965362 B2 JP6965362 B2 JP 6965362B2
Authority
JP
Japan
Prior art keywords
seq
polypeptide
derivative
amino acid
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019548059A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020509061A (ja
JP2020509061A5 (enExample
Inventor
ウェイ，ダ
ディン，イ
リ，シャオメイ
ユ，ウェン
チェン，シャオホン
シャオ，リン
チェン，ルイ
チェン，リン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Huitai Biomedicine Co ltd
Original Assignee
Chengdu Huitai Biomedicine Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201710115604.4A external-priority patent/CN106860855B/zh
Priority claimed from CN201710677602.4A external-priority patent/CN109384830B/zh
Application filed by Chengdu Huitai Biomedicine Co ltd filed Critical Chengdu Huitai Biomedicine Co ltd
Publication of JP2020509061A publication Critical patent/JP2020509061A/ja
Publication of JP2020509061A5 publication Critical patent/JP2020509061A5/ja
Application granted granted Critical
Publication of JP6965362B2 publication Critical patent/JP6965362B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2019548059A 2017-03-01 2018-02-28 ポリペプチド、ポリペプチド断片及びその誘導体、並びに応用 Active JP6965362B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201710115604.4 2017-03-01
CN201710115604.4A CN106860855B (zh) 2017-03-01 2017-03-01 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用
CN201710677602.4A CN109384830B (zh) 2017-08-09 2017-08-09 多肽、多肽片段及其衍生物在防治纤维化疾病中的应用
CN201710677602.4 2017-08-09
PCT/CN2018/077492 WO2018157807A1 (zh) 2017-03-01 2018-02-28 多肽、多肽片段及其衍生物与应用

Publications (3)

Publication Number Publication Date
JP2020509061A JP2020509061A (ja) 2020-03-26
JP2020509061A5 JP2020509061A5 (enExample) 2020-07-09
JP6965362B2 true JP6965362B2 (ja) 2021-11-10

Family

ID=63369746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019548059A Active JP6965362B2 (ja) 2017-03-01 2018-02-28 ポリペプチド、ポリペプチド断片及びその誘導体、並びに応用

Country Status (9)

Country Link
US (2) US12011475B2 (enExample)
EP (1) EP3590527A4 (enExample)
JP (1) JP6965362B2 (enExample)
KR (1) KR102368159B1 (enExample)
AU (1) AU2018227737B2 (enExample)
CA (1) CA3054839C (enExample)
IL (1) IL268971B2 (enExample)
SG (1) SG11201907914QA (enExample)
WO (1) WO2018157807A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240306T1 (hr) * 2015-10-27 2024-05-10 Taipei Medical University Derivati indolina za liječenje i/ili prevenciju fibroznih bolesti
CN112386678B (zh) * 2019-08-13 2023-07-07 成都惠泰生物医药有限公司 多肽或其衍生物的应用
JP7892764B2 (ja) * 2021-08-11 2026-07-21 イミュニティーバイオ インコーポレイテッド 多重鎖キメラポリペプチド及び肝疾患の治療におけるその使用
CN119384427A (zh) * 2022-06-23 2025-01-28 成都倍特新启生物医药有限责任公司 肽抑制剂及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9509957D0 (en) 1995-05-17 1995-07-12 Khalil Nasreen Post-translational activation of tgf-›1 involving the tsp-1 receptor cd36
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
AU765753B2 (en) 1999-05-17 2003-09-25 Conjuchem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20060270618A1 (en) 2001-12-18 2006-11-30 Dorian Bevec Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
AU2008303928A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of NF-KAPPAB inhibitor SN50 and optionally angiotensin III as therapeutic agents in the treatment of EG HBV infection
WO2009043525A2 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of the combination of gluten exorphin c and cd36 as a therapeutic agent
JP2014506117A (ja) * 2010-11-24 2014-03-13 エフ．ホフマン−ラ ロシュ アーゲー 軽度の炎症を検出するための方法
EP2714735B1 (en) 2011-06-03 2021-07-21 XOMA Technology Ltd. Antibodies specific for tgf-beta
WO2016054114A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
CN104313028A (zh) 2014-09-30 2015-01-28 北京生科东方科技有限公司 抗类风湿关节炎的小肽基因及其生产方法
CN105061600A (zh) 2015-09-05 2015-11-18 苏州普罗达生物科技有限公司 类风湿因子IgA抑制多肽及其应用
CN106860855B (zh) * 2017-03-01 2021-06-11 成都惠泰生物医药有限公司 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用

Also Published As

Publication number Publication date
IL268971A (en) 2019-10-31
US12011475B2 (en) 2024-06-18
KR102368159B1 (ko) 2022-03-03
IL268971B1 (en) 2023-09-01
WO2018157807A1 (zh) 2018-09-07
US20240390450A1 (en) 2024-11-28
JP2020509061A (ja) 2020-03-26
AU2018227737B2 (en) 2021-04-01
IL268971B2 (en) 2024-01-01
CA3054839A1 (en) 2018-09-07
CA3054839C (en) 2023-08-29
EP3590527A1 (en) 2020-01-08
AU2018227737A2 (en) 2020-01-30
AU2018227737A1 (en) 2019-10-17
KR20190125373A (ko) 2019-11-06
US20220072082A1 (en) 2022-03-10
EP3590527A4 (en) 2021-01-06
SG11201907914QA (en) 2019-09-27

Similar Documents

Publication Publication Date Title
CN106860855B (zh) 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用
CN109384830B (zh) 多肽、多肽片段及其衍生物在防治纤维化疾病中的应用
US20240390450A1 (en) Polypeptide, polypeptide fragment, derivative thereof, and applications thereof
EP2552470B1 (en) Peptides for promoting angiogenesis and an use thereof
Qi et al. Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice
JP6227601B2 (ja) 好中球活性化に起因する疾患の治療薬及び検査方法
TW201938794A (zh) 組合物及使用方法
TWI657823B (zh) 一種預防和治療系統性硬化症的方法
CA3047175A1 (en) Method for mitigating heart disease
HK1257585A1 (zh) 预防和治疗皮肤纤维化的药物及其用途
KR20190003546A (ko) 컨쥬게이트 c1 에스테라제 억제제 및 그의 용도
JP2020536065A (ja) 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
KR20030034238A (ko) 다발성 경화증의 치료에서 사용되는 케모킨 변이체
US20260115261A1 (en) Collagen peptide-based medicament compositions and uses thereof
EP2552940A2 (en) Peptides for promoting angiogenesis and an use thereof
US20070167369A1 (en) Novel use of isolated polypeptide comprising four FAS-1 domains, EM1 domain and RGD motif
CN103044554B (zh) 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
US20070004622A1 (en) Imidazole derivative, process for producing the same, and use
HK40015944A (en) Polypeptide, polypeptide fragment, derivative thereof, and applications thereof
US20110092427A1 (en) Polypeptide and pharmaceutical composition containing the polypeptide
JP2000086533A (ja) 新規なアレルギー治療剤
WO2021052277A1 (zh) 重组人神经调节蛋白衍生物及其用途
Qi et al. Tissue Inhibitor of Metalloproteinases-3 Peptides Inhibit Angiogenesis and Choroidal
JPWO2005077971A1 (ja) ヘビ毒由来の血管内皮増殖因子（ｖｅｇｆ）様タンパク質のヘパリン結合部位より設計された新規なヘパリン結合能を有するペプチドとその用途
HK1147502A (en) Polypeptide and pharmaceutical composition containing the polypeptide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210825

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210928

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211020

R150 Certificate of patent or registration of utility model

Ref document number: 6965362

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250